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Background: The aim of this study was to estimate associations between inflammatory markers and obesity indices
in normo- and hypertensive subjects.
Methods: 65 obese adult subjects were divided into two groups: (A) of hypertensives (n = 54) and (B) of
normotensives (n = 11). Waist circumference (WC), body mass index (BMI), waist-to-hip ratio (WHR), waist-to-height
ratio (WHtR), visceral adiposity index (VAI), body adiposity index (BAI) and tumor necrosis factor-α (TNF-α), interleukin
(IL)-6 and high sensitivity C-reactive protein (hsCRP) serum concentrations were estimated.
Results: In group A WHtR was higher (0.69 ± 0.07 vs 0.63 ± 0.06; p < 0.01), hsCRP correlated with BMI and WHtR
(r = 0.343; p = 0.011 and r = 0.363; p < 0.01, respectively). BAI correlated with hsCRP in group A and B (r = 0.329;
p < 0.05 and r = 0.642; p < 0.05; respectively) and in females and males (r = 0.305; p = 0.05 and r = 0.44; p < 0.05,
respectively). In females hsCRP was higher (3.2 ± 2.2 mg/l vs 2.1 ± 1.5 mg/l; p < 0.05). In patients without lipid
lowering treatment hsCRP and IL-6 were higher (3.2 ± 1.7 mg/l vs 2.4 ±2.2 mg/l; p = 0.01 and 15.9 ± 7.2 pg/ml vs
13.6 ± 9.9 pg/ml; p < 0.01, respectively).
Conclusions: WHtR is a sensitive index associated with chronic inflammation in obese hypertensive subjects.
BAI correlates with hsCRP independently of hypertension and sex. hsCRP is more sensitive marker associated with
obesity than IL-6 and TNF-α. Lipid lowering treatment influence chronic inflammation.
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Obesity is one of the most important social problems of
communities in developed countries. It has been reported
that obesity is associated with a low-grade inflammatory
process in the white adipose tissue (WAT) [1-10]. It is a
result of chronic activation of the immune system and
may contribute to the development of insulin resistance,
impaired glucose tolerance or diabetes [1,2]. Increased
mass of adipose tissue simultaneously activates the inflam-
matory process in WAT itself, in the liver and in immune
cells [3]. This process leads to increase of circulating levels
of proinflammatory cytokines, hormone-like molecules
and other inflammatory markers [3]. On the other hand,* Correspondence: stepm@op.pl
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stated.some mechanisms related mainly to the hypothalamic-
pituitary-adrenal axis and autonomic nervous system
are activated to counteract this obesity-related stress
[3]. Activation of these mechanisms increases levels of
glucocorticoids, which may induce the development
and differentiation of preadipocytes with further in-
crease of WAT as a result [3]. Moreover, enhanced secre-
tion of proinflammatory cytokines from enlarged WAT
may additionally stimulate the hypothalamic-pituitary-
adrenal axis [3].
WAT is a source of some proinflammatory cytokines
such as tumor necrosis factor alpha (TNF-α) and
interleukin-6 (IL-6), which may show both local and
systemic effects [1,5-8]. Results of some previously con-
ducted studies indicate that obese WAT is infiltrated by
macrophages, which may locally produce inflammatory cy-
tokines [1,2,6,7,10-13]. Macrophage infiltration of adiposeLtd. This is an Open Access article distributed under the terms of the Creative
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(BMI), body fat mass and adipocyte hypertrophy, and
this effect is reversible on weight loss [7]. Obesity-
related chronic inflammation is caused not only by in-
filtration by inflammatory immune cells but also by a
parallel loss or functional reprogramming of immuno-
regulatory cells [8,10,13]. In normal weighted subjects
WAT contains mainly M2 type macrophages which pro-
duce anti-inflammatory cytokines such as IL-10, IL-1 Ra
and arginase (inhibiting enzyme of nitric oxide synthase –
iNOS), whereas in obesity-related WAT, especially of vis-
ceral origin, M1 type macrophages dominate [3,8,10,11].
This type of macrophage is characterized by a specific sur-
face marker (CD11c+) and by production of iNOS and
classical proinflammatory markers [3]. Type M1 macro-
phages are stimulated by interferon-γ and lipopolysaccha-
rides to release TNF-α and IL-6 and to produce reactive
oxygen species (ROS) [11]. Thus, obesity-related inflam-
mation is associated with a switch from the M2 to M1
phenotype, especially in visceral adipose tissue, which
forms “crown-like structures” (CLS) constituted by dead
adipocytes and adipocyte cellular fragments [2,3,12].
Rapid increase of fat mass in obese subjects may be as-
sociated with hypoperfusion and adipose hypoxia which
may induce both oxidative and endoplasmic reticulum
stress contributing to release of inflammatory mediators
[3,7,9]. Enhanced expression of proinflammatory cyto-
kines may also be a result of increased activation of both
c-jun N-terminal kinase and inhibitor of k-kinase [4].
Obesity-related changes were observed in inflammasome,
which is a macromolecular innate immune cell sensor ini-
tiating the inflammatory response [4]. One of the struc-
tural parts of inflammasome are monomers containing
NOD-like receptors (NLRs) and one of them, NLRP3, is
related to metabolic stress, insulin resistance and type 2
diabetes [4]. Activation of NLRP3 leads to stimulation of
macrophage-mediated T cells in adipose tissue with im-
pairment of insulin sensitivity as a result [4]. Hypergly-
cemia and some substances such as reactive oxygen
species (ROS), palmitate, lipopolysaccharides and uric acid
can induce inflammasome activation [4].
TNF-α, IL-6 and the inflammasome-activated IL-1β are
the most important cytokines responsible for the chronic
inflammatory process [4-6,12,13]. Elevated levels of circu-
lating TNF-α were observed in obese subjects [4-14].
TNF-α is a cytokine not only associated with inflamma-
tion but also plays an important role in the development
of the immune system, induces adipocyte apoptosis and
also shows numerous effects in adipose tissue, especially
in lipid metabolism and insulin signaling [4,6,8,10,13,14].
TNF-α stimulates secretion of another proinflammatory
cytokine, IL-6 [4,10-14]. IL-6 is produced by adipose
tissue, endothelial cells (especially by the stromal vascu-
lar fraction), fibroblasts, macrophages, monocytes andlymphocytes, and contributes to acute phase reactions
and chronic inflammatory processes, regulation of en-
ergy homeostasis and to other important processes
[4,6,10,13,14]. This cytokine also plays an important
role in chronic inflammation in both obesity and insu-
lin resistance [4,6,10,13,14].
C-reactive protein (CRP) is a very sensitive marker of in-
flammation, which is synthesized in the liver, and this
process is regulated predominately by IL-6 [4,6]. CRP is
positively correlated with abdominal fat and closely corre-
lated with increased risk of cardiovascular events [4,12].
Results obtained from some studies indicate that adi-
pose body mass is related to chronic inflammation and
that visceral obesity is associated with elevated CRP
levels measured by a high-sensitivity method (hsCRP)
independently from BMI [4,15]. Circulating levels of
CRP, IL-6 and TNF-α were elevated in healthy obese
subjects in adults and also in children compared to nor-
mal weighted volunteers [4,13].
The causes and mechanisms of obesity-induced chronic
inflammation as well as the association between inflam-
matory markers or cytokines and obesity parameters are
still not fully explained. It is worth noting that obesity very
often coexists with hypertension, which is also associated
with a chronic inflammatory process [15-19]. Therefore
the aim of this study was to evaluate associations be-
tween inflammatory markers or cytokines such as IL-6,
TNF-α and hsCRP, and both classical and newer obesity
parameters and indices in obese normo- and hyperten-
sive subjects.
Material and methods
Sixty-five obese (BMI ≥ 30 kg/m2) non-diabetic Caucasian
out-patients of both sexes (25 males and 40 females) aged
from 35 to 64 years were enrolled in the study. Patients
were consecutively recruited between the 1st of June and
15th of December 2010. Patients with acute or chronic in-
flammation or those with hsCRP levels above 10 mg/l,
psychiatric disorders, pregnancy, cancer, severe hepatic or
renal diseases and acute cardiovascular events or with a
history of abdominal surgery, which could have any im-
pact on abdominal fat distribution, were excluded from
the study.
Participants were divided into 2 basic groups: (A) –
hypertensives (n = 54); and (B) – normotensives (n = 11).
All the subjects were divided according to serum levels
of hsCRP into the following 3 groups: group 1 – pa-
tients with low cardiovascular risk (CVR) (hsCRP <
1 mg/l), n = 11; group 2 – patients with medium CVR
(hsCRP between 1 and 3 mg/l), n = 30; and group 3 with
high CVR (hsCRP > 3 mg/l), n = 24. All the patients were
additionally analysed on the basis of sex: males (n = 20)
and females (n = 35), to estimate sex-dependent differ-
ences. All the study participants were also divided into 2
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fibrates or both) and not receiving lipid lowering treat-
ment to estimate the impact of this therapy on serum
levels of hsCRP, IL-6 and TNF-α.
After taking their medical history all the subjects had
blood pressure (BP) and pulse measured 3 times after a
10 min rest with an OMRON M4 Plus automated device
using the left upper arm and averaged. All the study par-
ticipants were evaluated for their body mass (BM),
height, waist (measured at a level midway between the
lowest rib and the iliac crest) and hip (widest diameter
over greater trochanters) circumferences (WC and HC,
respectively) to calculate obesity indices as follows:
1) Body mass index
BMI = weight/height2 (kg/m2)
2) Waist-to-hip ratio
WHR =waist circumference (cm)/hip circumference
(cm)
3) Waist-to-height ratio
WHtR = waist (cm)/height (cm)
Normally ranges from 0.46 to 0.62 [20]
4) Visceral adiposity index
VAI for:
Males ¼ WC

















Normal value = 1 in healthy non-obese subjects with
normal adipose distribution and normal TG and
HDL-C levels [21];
5) Body adiposity index
BAI ¼ Hip circumference
Height mð Þ1:5 −18
in which hip circumference is measured in cm [22].
Serum TNF-α and IL-6 concentrations were esti-
mated using an ELISA method (DRG Instruments GmbH,
Marburg, Germany) in fasting venous blood samples.
Serum high-sensitivity C-reactive protein (hsCRP) levels
were measured by immunoturbidimetry. Serum levels of
triglyceride (TG) and high-density lipoprotein cholesterol
(HDL-C) were measured to calculate VAI.
The study protocol was approved by the local Bio-
ethical Committee and informed consent was obtained
from all the patients.
Statistical analysis
Results are presented as means ± standard deviation (SD).
Some of the data were also expressed as proportions (%).
The assumption of normality was assessed with theShapiro-Wilk test. Homogeneity of variances was veri-
fied with Levene’s test. Significance of differences between
means from two compared groups were determined by
Student’s t-test or by one-way analysis of variances
(ANOVA) with post-hoc Scheffé test for detailed multiple
comparisons (more than two groups). Chi-square tests
were used for comparison of categorical variables.
When the distribution of the variables was not normal
in at least one of the compared groups Mann-Whitney
U-test and Kruskal-Wallis analysis of variances with
post-hoc Conover-Inman tests were applied. Spearman's
rank correlation coefficient (r) was used to estimate the
correlation between variables from comparative groups.
P values <0.05 were considered significant.
Results
Clinical characteristics of investigated groups are pre-
sented in Tables 1, 2 and 3 and the results are presented
in Tables 4, 5, 6, 7, 8, 9, 10 and 11.
Hypertensive obese patients (group A) were older than
normotensive participants from group B (57.9 ± 11.0 vs
46.1 ± 10.8 years; p = 0.001; Table 1) and in comparison to
group B they more often received angiotensin-converting
enzyme inhibitors (ACEI) (81.5% vs 9.1%; p < 0.0001),
angiotensin II receptor antagonists (ARB) (p = 0.05), di-
uretics (64.8% vs 9.1%; p < 0.01) and calcium channel an-
tagonists (CCA) (p < 0.05) (Table 1).
Females dominate in group 3 with high cardiovascu-
lar risk (CVR) compared to group 1 and 2 (83.3% vs
36.4%; p < 0.05 and 83.3% vs 53.3%; p < 0.05, respect-
ively; Table 2). Subjects from group 3 compared to
group 2 received more seldom ACEI but more often
spironolactone (45.8% vs 90.0%; p < 0.01 and 45.8% vs
16.7%; p < 0.05, respectively; Table 2). Subjects with low
CVR from group 1 received more often hypolipemic
drugs (statins, fibrates) compared to group 2 and 3
(90.9% vs 50.0%; p < 0.05 and 90.9% vs 41.7%; p < 0.01,
respectively; Table 2).
Myocardial infarction and cerebral artery failure oc-
curred more often in obese males compared to females
(24.0% vs 5.0%; p < 0.05 and 12.0% vs 0%; p = 0.053, re-
spectively; Table 3). On the other hand, obese females
suffered more often from cardiac failure and chronic
kidneys disease (CKD) (45.0% vs 28.0%; p < 0.05 and
32.5% vs 8,0%; p < 0.05, respectively; Table 3). Females
received more often diuretics but more rarely α1-adren-
ergic receptor antagonists than males (67.5% vs 40.0%;
p < 0.05 and 2.5% vs 24.0%; p = 0.01, respectively; Table 3).
Obese hypertensive patients (group A) had higher
mean systolic blood pressure (SBP) compared to normo-
tensive subjects from group B (139.2 ± 16.5 mmHg vs
121.3 ± 9.9 mmHg; p = 0.001; Table 4). Mean WHtR was
higher in group A compared to group B (0.69 ± 0.07 vs
0.63 ± 0.06; p < 0.01; Table 4). In group A hsCRP serum





Group A Group B Statistical







Age (years) 57.9 ± 11.0 46.1 ± 10.8 p = 0.001
Ischemic heart
disease
18 (33.3%) 2 (18.2%) NS
Myocardial infarct 7 (13.0%) 1 (9.1%) NS
Cardiac failure 22 (40.7%) 3 (27.3%) NS
IFG/IGT 34 (63.0%) 4 (36.4%) NS
CKD 14 (25.9%) 1 (9.1%) NS
Stroke 3 (5.6%) 0 NS
Cerebral arteries
failure
3 (5.6%) 0 NS
Hyperuricemia 24 (44.4%) 2 (18.2%) NS
Dyslipidaemia 52 (96.3%) 9 (81.8%) NS
Tobacco smoking 5 (9.3%) 0 NS
ACEI 44 (81.5%) 1 (9.1%) p < 0.0001
ARB 17 (31.5%) 0 p = 0.05
Diuretics 35 (64.8%) 1 (9.1%) p < 0.01
CCA 19 (35.2%) 0 p < 0.05
BB 23 (40.7%) 2 (18.2%) NS
Spironolactone 17 (31.5%) 1 (9.1%) NS
ARA 7 (13.0%) 0 NS
ASA 15 (27.8%) 1 (9.1%) NS
Hypolipemic
treatmenta
31 (57.4%) 4 (36.4%) NS
IFG – impaired fasting glucose. IGT – impaired glucose tolerance. CKD – chronic
kidney disease. COPD – chronic pulmonary obstructive disease. ACEI – angiotensin-
converting enzyme inhibitor. ARB – angiotensin II receptor antagonist.
CCA – calcium channel antagonist. BB – β-adrenergic receptor blocker.
ARA – α1-adrenergic receptor antagonist. ASA – acetylsalicylic acid. NS – not
significant. a – statins and/or fibrates.
Table 2 Clinical characteristics of the patient groups
according to hs-CRP level (cardiovascular risk)
Compared groups and
clinical data
Group 1 Group 2 Group 3
low CVR medium CVR high CVR
n = 11 n = 30 n = 24
Males 7 (63.6%) 14 (46.7%) 4 (16.7%)
Females 4 (36.4%) 16 (53.3%) 20 (83.3%)*^
Ages (years) 56.6 ± 12.7 55.4 ± 9.9 57.2 ± 13.0
Hypertension 8 (72.7%) 26 (86.7%) 20 (83.3%)
Ischemic heart disease 3 (27.3%) 11 (36.7%) 6 (25.0%)
Myocardial infarct 1 (9.1%) 6 (20.0%) 1 (4.2%)
Cardiac failure 3 (27.3%) 11 (36.7%) 11 (45.8%)
IFG/IGT 5 (45.5%) 21 (70.0%) 12 (50.0%)
CKD 1 (9.1%) 7 (23.3%) 7 (29.2%)
Stroke 0 1 (3.3%) 2 (8.3%)
Cerebral arteries failure 1 (9.1%) 2 (6.7%) 0
Hyperuricemia 3 (27.3%) 11 (36.7%) 12 (50.0%)
Dyslipidemia 11 (100.0%) 29 (96.7%) 21 (87.5%)
Tobacco smoking 0 3 (10.0%) 2 (8.3%)
ACEI 9 (81.8%) 27 (90.0%) 11 (45.8%)^^
ARB 1 (9.1%) 6 (20.0%) 10 (41.7%)
Diuretics 6 (54.5%) 16 (53.3%) 16 (66.7%)
CCA 4 (36.4%) 10 (33.3%) 6 (25.0%)
BB 3 (27.3%) 10 (33.3%) 12 (50.0%)
Spironolactone 2 (18.2%) 5 (16.7%) 11 (45.8%)^
ARA 2 (18.2%) 4 (13.3%) 1 (4.2%)
ASA 1 (9.1%) 11 (36.7%) 5 (20.8%)
Hypolipemic treatmenta 10 (90.9%) *15 (50.0%) **10 (41.7%)
*p < 0.05; **p < 0.01; vs Group 1; ^P < 0.05 vs Group 2; ^^P < 0.01 vs Group 2;
CVR – cardiovascular risk, a – statins and/or fibrates.
Stępień et al. Lipids in Health and Disease 2014, 13:29 Page 4 of 10
http://www.lipidworld.com/content/13/1/29levels positively correlated with BMI, WHtR and BAI
(r = 0.343; p = 0.011; r = 0.363; p < 0.01 and r = 0.329;
p < 0.05, respectively) and IL-6 serum concentrations posi-
tively correlated with VAI (r = 0.281; p < 0.05) (Table 5).
In group B positive correlations were observed between
hsCRP serum levels and BAI as well as between IL-6
serum concentrations and WHtR (r = 0.642; p < 0.05 and
r = 0.6; p = 0.05, respectively; Table 6).
Mean WHtR was higher in patients with high CVR from
group 3 compared to group 1 and 2 (0.71 ± 0.07 vs 0.64 ±
0.06; p < 0.01 and 0.71 ± 0.07 vs 0.67 ± 0.06; p < 0.05, re-
spectively; Table 7). Mean BMI was higher in group 3 com-
pared to group 1 (38.1 ± 5.4 kg/m2 vs 33.4 ± 1.8 kg/m2;
p < 0.05; Table 7). Mean BAI was higher in group 3 than
in group 1 and 2 (42.8 ± 8.1 vs 33.3 ± 5.9; p < 0.01 and
42.8 ± 8.1 vs 37.1 ± 5.3; p < 0.01, respectively; Table 7).Mean hsCRP serum concentration was higher in group
3 in comparison to groups 1 and 2 (4.9 ± 1.7 mg/l vs
0.83 ± 0.26 mg/l; p < 0.0001 and 4.9 ± 1.7 mg/l vs 1.8 ±
0.6 mg/l; p < 0.0001, respectively; Table 7). Mean hsCRP
serum level was higher in group 2 compared to group 1
(1.8 ± 0.6 mg/l; p < 0.0001; Table 7). Mean IL-6 serum
concentration was higher in group 3 than in group 1
and 2 (17.7 ± 9.4 pg/ml vs 10.0 ± 3.5 pg/ml; p < 0.01 and
17.7 ± 9.4 pg/ml vs 13.9 ± 8.9 pg/ml; p < 0.05, respect-
ively; Table 7).
In males mean WC and mean WHR were higher than in
females (117.0 ± 10.8 cm vs 108.5 ± 10.4 cm; p < 0.01 and
1.01 ± 0.06 vs 0.91 ± 0.06; p < 0.0001, respectively; Table 8).
On the other hand, in females mean BAI and hsCRP serum
concentrations were higher than in the male group (41.7 ±
6.9 vs 33.5 ± 5.0; p < 0.0001 and 3.2 ±2.2 mg/l vs 2.1 ±
1.5 mg/l; p < 0.05, respectively; Table 8).
In females hsCRP serum levels positively correlated with
WHtR (r = 0.321; p < 0.05) and BMI and BAI (r = 0.305;







n = 40 n = 25
Age (years) 57.9 ± 11.0 52.6 ± 12.3 NS
Hypertension 34 (85.0%) 20 (80.0%) NS
Ischemic heart disease 9 (22.5%) 11 (44.0%) NS
Myocardial infarct 2 (5.0%) 6 (24.0%) p < 0.05
Cardiac failure 18 (45.0%) 7 (28.0%) p < 0.05
IFG/IGT 21 (52.5%) 17 (68.0%) NS
CKD 13 (32.5%) 2 (8.0%) p < 0.05
Stroke 2 (5.0%) 1 (4.0%) NS
Cerebral arteries failure 0 3 (12.0%) p = 0.053
Hyperuricemia 17 (42.5%) 14 (56.0%) NS
Dyslipidemia 37 (92.5%) 24 (96.0%) NS
Tobacco smoking 2 (5.0%) 3 (12.0%) NS
ACEI 31 (77.5%) 15 (60.0%) NS
ARB 13 (32.5%) 4 (16.0%) NS
Diuretics 27 (67.5%) 10 (40.0%) p < 0.05
CCA 12 (30.0%) 7 (28.0%) NS
BB 17 (42.5%) 8 (32.0%) NS
Spironolactone 14 (35.0%) 4 (16.0%) NS
ARA 1 (2.5%) 6 (24.0%) p = 0.01
ASA 10 (25.0%) 7 (28.0%) NS
Hypolipemic treatmenta 20 (50.0%) 15 (60.0%) NS
a – statins and/or fibrates.
Table 4 Results obtained in obese hypertensive and
normotensive patients
Parameters Group A Group B Statistical
significance pN = 54 N = 11
SBP (mmHg) 139.2 ± 16.5 121.3 ± 9.9 p = 0.001
DBP (mmHg) 86.7 ± 9.5 81.1 ± 5.2 NS
HR (min-1) 74.7 ± 10.1 77.8 ± 8.1 NS
WC (cm) 112.8 ± 11.5 106.6 ± 8.7 NS
WHR 0.95 ± 0.08 0.92 ± 0.05 NS
WHTR 0.69 ± 0.07 0.63 ± 0.06 p < 0.01
BMI (kg/m2) 36.5 ± 4.8 34.7 ± 3.1 NS
BAI 39.3 ± 7.4 35.0 ± 6.1 NS
VAI 2.1 ± 1.1 1.9 ± 1.0 NS
hs-CRP (mg/l) 2.8 ± 1.9 2.7 ± 2.5 NS
IL-6 (pg/ml) 14.6 ± 9.1 14.9 ± 7.3 NS
TNF-α (pg/ml) 6.2 ± 1.8 6.7 ± 1.9 NS
SBP – systolic blood pressure, DBP – diastolic blood pressure.
Table 5 Correlations between estimated parameters in
group A (n = 54)
Parameters hs-CRP IL-6 TNF-α
(mg/l) (pg/ml) (pg/ml)
WC (cm) 0.211 -0.021 0.111
NS NS NS
BMI (kg/m2) 0.343 0.054 0.185
p = 0.011 NS NS
WHR -0.107 -0.075 -0.093
NS NS NS
WHTR 0.363 0.070 0.187
p < 0.01 NS NS
BAI 0.329 0.098 0.094
p < 0.05 NS NS
VAI 0.188 0.281 0.229
NS p < 0.05 NS
Data are expressed as r – Spearman’s rank correlation with statistical
significance p.
Stępień et al. Lipids in Health and Disease 2014, 13:29 Page 5 of 10
http://www.lipidworld.com/content/13/1/29p = 0.05, and r = 0.309; p = 0.05, respectively; Table 9). In
males hsCRP serum concentrations positively correlated
with WHtR, BAI and VAI (r = 0.458; p < 0.05; r = 0.440;
p < 0.05 and r = 0.443; p < 0.05, respectively), IL-6 serum
concentrations positively correlated with VAI (r = 0.472;
p < 0.05) and TNF-α serum concentrations negatively cor-
related with WHR (r = - 0.408; p < 0.05) (Table 10).
Patients receiving hypolipemic treatment (statins, fibrates
or both) were older compared to the subjects without this
treatment (58.8 ± 11.1 years vs 52.4 ± 11.7 years; p < 0.01;
Table 11). In the group of patients not receiving hypolipe-
mic agents mean serum concentrations of hsCRP and IL-6Table 6 Correlations between estimated parameters in
group B (n = 11)
Parameters hs-CRP IL-6 TNF-α
(mg/l) (pg/ml) (pg/ml)
WC (cm) -0.297 0.069 0.254
NS NS NS
BMI (kg/m2) -0.014 0.046 0.292
NS NS NS
WHR -0.429 0.329 0.126
NS NS NS
WHTR 0.393 0.600 -0.261
NS P = 0.05 NS
BAI 0.642 0.347 -0.265
p < 0.05 NS NS
VAI 0.333 0.455 -0.167
NS NS NS
Data are expressed as r – Spearman’s rank correlation with statistical
significance p.
Table 7 Results obtained in the patient groups divided
according to hs-CRP level (cardiovascular risk)
Compared
data
Group 1 Group 2 Group 3
(low CVR) (medium CVR) (high CVR)
n = 11 n = 30 n = 24
RRs (mmHg) 135.0 ± 18.3 132.7 ± 14.1 141.0 ± 19.1
RRr (mmHg) 84.1 ± 10.6 84.2 ± 7.8 88.6 ± 9.7
HR (min-1) 75.3 ± 9.1 75.4 ± 10.7 75.0 ± 9.4
WC (cm) 109.3 ± 9.7 111.5 ± 11.1 113.2 ± 12.3
WHR 0.98 ± 0.10 0.95 ± 0.08 0.92 ± 0.06
WHTR 0.64 ± 0.06 0.67 ± 0.06 **0.71 ± 0.07#
BMI (kg/m2) 33.4 ± 1.8 35.7 ± 4.0 *38.1 ± 5.4
BAI 33.3 ± 5.9 *37.1 ± 5.3 **42.8 ± 8.1##
VAI 1.7 ± 1.0 2.2 ± 1.2 2.1 ± 1.0
hsCRP (mg/l) 0.83 ± 0.26 ***1.8 ± 0.6 ***4.9 ± 1.7###
IL6 (pg/ml) 10.0 ± 3.5 13.9 ± 8.9 **17.7 ± 9.4#
TNF-α (pg/ml) 6.7 ± 2.8 6.3 ± 1.6 6.1 ± 1.4
*p < 0.05; **p < 0.01; ***P < 0.0001 vs Group 1; #p < 0.05; ##p < 0.01; ###P <
0.0001 vs Group 2.
Table 9 Correlations between estimated parameters in
female groups (n = 40)
Parameters hs-CRP IL-6 TNF-α
(mg/l) (pg/ml) (pg/ml)
WC (cm) 0.265 0.094 0.269
NS NS NS
BMI (kg/m2) 0.305 0.075 0.251
P = 0.05 NS NS
WHR 0.038 0.171 0.023
NS NS NS
WHTR 0.321 0.071 0.294
p < 0.05 NS NS
BAI 0.309 -0.009 0.211
P = 0.05 NS NS
VAI 0.128 0.239 0.143
NS NS NS
Data are expressed as r – Spearman’s rank correlation with statistical
significance p.
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mic treatment (3.2 ± 1.7 mg/l vs 2.4 ± 2.2 mg/l; p = 0.01
and 15.9 ± 7.2 pg/ml vs 13.6 ± 9.9 pg/ml; p < 0.01, respect-
ively; Table 11).
Discussion
It was reported that both hypertension and obesity are
associated with chronic inflammation [1-18]. Therefore
one could expect significant differences in serum levels
of hsCRP, IL-6 and TNF-α between obese normoten-
sive and hypertensive subjects. Nevertheless, we didTable 8 Results obtained in the patient groups divided
by sex
Compared data Females Males Statistical
significance pn = 40 n = 25
Hypolipidemic treatment 20 (50.0%) 15 (60.0%) NS
SBP (mmHg) 137.1 ± 17.7 134.5 ± 15.9 NS
DBP (mmHg) 86.0 ± 9.4 85.5 ± 8.9 NS
HR (min-1) 75.1 ± 9.6 75.5 ± 10.3 NS
WC (cm) 108.5 ± 10.4 117.0 ± 10.8 p < 0.01
WHR 0.91 ± 0.06 1.01 ± 0.06 P < 0.0001
WHTR 0.68 ± 0.07 0.67 ± 0.06 NS
BMI (kg/m2) 36.2 ± 4.8 36.1 ± 4.3 NS
BAI 41.7 ± 6.9 33.5 ± 5.0 P < 0.0001
VAI 2.0 ± 1.0 2.1 ± 1.3 NS
hs-CRP (mg/l) 3.2 ± 2.2 2.1 ± 1.5 p < 0.05
IL-6 (pg/ml) 16.7 ± 10.4 11.5 ± 3.7 NS
TNF-α (pg/ml) 6.2 ± 1.4 6.5 ± 2.2 NSnot observe any significant difference in the serum
mean concentrations of inflammatory markers between
the compared groups. We suggest that it might result
from the small sizes of both groups, especially of normo-
tensive participants. We cannot exclude that it might also
be related to angiotensin-converting enzyme inhibitors
(ACEI) and angiotensin II receptor antagonists (sartans,
ARB), which significantly dominated in the group of
hypertensive obese patients. There is more evidence that
angiotensin II blockade by both ACEI and ARB may sig-
nificantly reduce concentrations of proinflammatory me-
diators and oxidative stress products in numerous modelsTable 10 Correlations between estimated parameters in
male groups (n = 25)
Parameters hs-CRP IL-6 TNF-α
(mg/l) (pg/ml) (pg/ml)
WC (cm) 0.362 0.023 -0.074
NS NS NS
BMI (kg/m2) 0.367 -0.061 0.014
NS NS NS
WHR 0.262 0.062 -0.408
NS NS p < 0.05
WHTR 0.458 0.066 -0.191
p < 0.05 NS NS
BAI 0.440 0.071 -0.135
p < 0.05 NS NS
VAI 0.443 0.472 0.142
p < 0.05 p < 0.05 NS
Data are expressed as r – Spearman’s rank correlation with statistical
significance p.
Table 11 Results obtained in the patient groups divided







(N = 35) (N = 30)
Hypertension 31 (88.6%) 23 (76.7%) NS
Age (years) 58.8 ± 11.1 52.4 ± 11.7 p < 0.01
61.0 (56.0-64.0) 54.0 (45.5-60.8)
Males 15 (42.9%) 10 (33.3%) NS
hs-CRP (mg/l) 2.4 ± 2.2 3.2 ± 1.7 P = 0.010
1.7 (1.0-3.5) 3.0 (1.8-4.4)
IL-6 (pg/ml) 13.6 ± 9.9 15.9 ± 7.2 p < 0.01
10.3 (8.9-14.5) 14.5 (10.3-18.9)
TNF-α (pg/ml) 6.3 ± 1.7 6.3 ± 1.9 NS
6.3 (5.5-7.1) 6.0 (4.9-7.1)
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effects is not fully explained [16,17]. We can also speculate
that hypolipemic treatment [more often in the hyperten-
sive group] might also have an impact on the result; how-
ever, the difference observed between the groups did not
reach statistical significance.
The results of our study suggest that WHtR, a new
index of visceral obesity, may be a more sensitive obesity
index associated with chronic inflammation in obese
hypertensive patients. WHtR was also higher in obese
patients with high and medium CVR. Lapice et al. ob-
served a relationship between abdominal obesity (WHR,
WC) and hsCRP independently of BMI and sex in non-
diabetic subjects with abdominal obesity [23]. Arbel et al.
in a large population (n = 13,033) study found associations
between hsCRP and obesity indices such as WC, BMI,
BAI, WHR and WHtR, where the strongest correlations
were observed for BMI, WC and WHtR [24]. Significant
correlations between hsCRP and BMI, WHtR and BAI in
obese subjects were also noted in our previously con-
ducted study [25]. The aforementioned Arbel et al. also
found higher hsCRP in females compared to males [24].
Similar to these findings we observed higher hsCRP in fe-
males and we suppose that it might result from higher adi-
posity, described by BAI, which was higher in women.
Our findings are in agreement with results published by
Pannacciulli et al., who observed a positive association be-
tween hsCRP and total body fat as well as with central fat
in adult women [26]. Therefore we suggest that obesity
chronic inflammation is more evident in the women com-
pared to the men.
Strong correlations between hsCRP and BAI as well as
with BMI and WC were observed by Lichtash et al. in
adult Mexican Americans independently of the sex
[27]. These results are confirmed by our observations
for BMI and BAI in hypertensive obese patients,although we found some sex-dependent differences for
BMI (a significant association only in females) and with
the correlation between hsCRP and BAI on the border
of statistical significance in females. Result obtained in
our present study from obese hypertensive subjects as
well as from the female group are in agreement with
data published by Thung-Wei et al. [28]. The authors
based on data from the NHANES study [n = 8 453]
found a strong positive correlation between BMI and
hsCRP in adult participants [28]. Results obtained in
our study are also in agreement with data published by
Engeli et al., who observed a strong correlation be-
tween hsCRP and BMI in obese women [29].
Similarly as in our previously conducted studies we
did not observe significant differences in BMI between
sexes [19,30]. Nevertheless, parameters of visceral obes-
ity such as WC and WHR are higher in females than in
males, whereas BAI – a parameter of adiposity – was
higher in women. These results are in agreement with
our previously obtained results and with the data re-
ported by other authors, who did find sex-dependent dif-
ferences in distribution of fat tissue, involving both size
and number of adipocytes [19,30,31]. Adipocytes from
gluteo-femoral fat tissue in females are more numerous
and larger whereas visceral adipocytes are smaller than
in males [31]. However, the sizes of abdominal subcuta-
neous adipocytes are comparable between both sexes
[31]. Sex-dependent differences in fat distribution are
well established [31,32]. In comparison to males, who
often have more fat tissue in the central or abdominal re-
gion, females have more body fat with relatively greater
distribution in the hips and thighs [31,32]. Compared to
the men, women have more subcutaneous adipose tissue
and less visceral adipose tissue [32]. Adipose tissue distri-
bution in females changes with age. Therefore in post-
menopausal women there is an increased amount of
visceral adipose tissue [32].
It should be taken into consideration that although fat
accumulation in the subcutaneous abdominal area is as-
sociated with adipocyte hypertrophy in both women and
men, females primarily started with a greater number of
adipocytes which can later accumulate as greater fat
mass [31]. It is well known that both human adipocytes
and preadipocytes express sex steroid receptors [31,32].
Nevertheless, it was suggested that sex hormones pri-
marily affect adipose tissue indirectly by the central ner-
vous system [31,32]. Results obtained from in vitro
studies indicate that estrogens stimulate proliferation of
human preadipocytes in contrast to androgens, which
inhibit differentiation of these cells without affecting
proliferation [31].
Based on the data obtained from our present study, we
suggest that adiposity, especially described by BAI, may
be related to chronic inflammation independently from
Stępień et al. Lipids in Health and Disease 2014, 13:29 Page 8 of 10
http://www.lipidworld.com/content/13/1/29hypertension and sex. Moreover, WHtR – a newer index
of visceral obesity – may be a more sensitive predictor
of obesity-related chronic inflammation in both sexes as
well as in hypertensive obese patients than classical pa-
rameters such as WC and WHR. In obese males VAI
may be a valuable new parameter of visceral obesity as-
sociated with the chronic inflammatory process.
Park et al. observed that CRP was significantly associ-
ated with BMI whereas IL-6 better correlated with vis-
ceral obesity in obese subjects [33]. These findings
partially agree with some results obtained in our study.
We observed a significant correlation between IL-6 only
with some newer indices of visceral obesity such as VAI
and WHtR, whereas hsCRP also significantly correlated
with BMI and BAI. We suppose that the lack of signifi-
cant correlations between classical visceral obesity indi-
ces such as WC or WHtR and markers of inflammation
observed in our study might result from the small sizes
of the groups. We suggest that newer visceral obesity in-
dices such as WHtR and VAI may be more sensitive vis-
ceral obesity indices, as proposed by others [20,21]. In
contrast to our findings, Saijo et al. observed significant
correlations between CRP and classical visceral obesity
parameters such as WC and WHR [34].
Strong correlations between BMI and both hsCRP and
TNF-α serum levels were observed by Khan et al. in
non-diabetic obese subjects [35]. The authors also sug-
gested that TNF-α may be associated with CVR [35].
Nevertheless, we did not observe significant differences
in mean TNF-α levels between patient groups divided
according to CVR. Based on results obtained in our
study it seems that IL-6 similarly to hsCRP is more asso-
ciated with CVR than TNF-α. Higher mean CRP plasma
level and a positive correlation between IL-6 and WHtR
was found by Gharipour et al. in subjects with metabolic
syndrome; however, the authors did not observe signifi-
cant relationships between CRP levels and obesity pa-
rameters such as BMI, WHtR and WC in this study
group [36]. We noted a similar association between IL-6
and WHtR, but on the border of statistical significance
in the obese normotensive group. It is worth noting that
Gharipour et al. did not distinguish subgroups for those
with or without hypertension in the population of pa-
tients with metabolic syndrome [36].
In our study BMI and WC did not correlate with IL-6
and TNF-α in any investigated subgroups. These find-
ings are in agreement with results obtained by Agraval
et al., who also did not observe any significant correl-
ation between IL-6 and TNF-α with BMI and WC in a
North Indian healthy general population as well in both
sexes; however, the TNF-α serum level was higher in
obese subjects compared to non-obese participants [37].
In contrast we observed a significant inverse correlation
between WHR and TNF-α in the obese male group.Based on the data obtained from our study it is difficult
to explain this surprising relationship.
The results of our study confirm the anti-inflammatory
effect of statins and fibrates. Hypolipemic treatment led to
significant decrease of hsCRP and IL-6 mean serum levels
but without any impact on TNF-α serum concentration.
These findings are in agreement with previously published
data [38-40]. All the authors cited above observed a simi-
lar impact of statins or fibrates on hsCRP and IL-6 with-
out changing plasma or serum levels of TNF-α [38-40].
Hypolipemic treatment might also have an impact on ob-
tained results in the groups divided according hsCRP
level. In the group of subjects with high and medium CVR
we observed higher BMI, WHtR and BAI as well as higher
IL-6 mean serum levels compared to the group with low
CVR. These results confirm the relationships between
mentioned above obesity parameters and hsCRP in other
study groups. It should be taken into consideration that
sex and some agent might have an impact on these results.
Its worth noting that in group 3 with high CVR females
dominated and the subjects from this group received
more seldom lipid lowering agents as well as ACEI com-
pared to the other groups. As mentioned above, both
groups of these agents may have an impact on chronic in-
flammation. On the other hand, higher values of BMI,
WHtR and BAI may be indicators of CVR, as was previ-
ously reported [20-28,33,35].
The mechanism of anti-inflammatory action of lipid
lowering agents remains not fully explained. It is well
documented that IL-6 is produced by adipocyte tissue in
proportion to fat mass and hsCRP plasma levels are also
associated with adipose tissue [40]. However, it was not
established whether fibrates reduced hsCRP directly by
their impact on the liver or on the vascular bed [38]. It
has been suggested that fenofibrate may reduce systemic
inflammation by actions on multiple tissues [38]. It is
proposed that fibrates lead to increase of IL-6 synthesis
via PPAR-α receptors with reduction of hsCRP plasma
levels as a result [38]. It was reported that PPAR-α re-
ceptors are abundant in the vascular bed and fenofibrate
may improve endothelial function as well as vascular re-
activity by decreasing ICAM/VCAM plasma levels [38].
Some authors suggest that statins may inhibit macro-
phage activity and subsequent production of cytokines
and tissue factors as well as inhibition of matrix metallo-
proteinase activity and reduction of inflammatory cell
function as a result [40]. It is well known that CRP syn-
thesis is also IL-6 dependent, so that decrease of IL-6
plasma levels in subjects receiving statins might also be
partially responsible for reduction of plasma hs-CRP con-
centrations, but one cannot exclude a direct impact of sta-
tins on inhibition of CRP synthesis independently from
IL-6 [40]. Although TNF-α is also synthesized by adipo-
cytes, its metabolism is not so directly associated with
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suggest that statins may act via different immune mecha-
nisms in obesity-related chronic inflammation [40-43].
Our study has some limitations. The most important
one is the relatively small study population which might
not be able to show some significant relationships be-
tween compared groups. The small size of study groups
makes us unable to categorize inflammatory markers
into elevated and normal levels. We also cannot exclude
age-related differences between compared groups; how-
ever, because of the small study population we did not
consider this parameter. It should be also noted that
there are very limited data obtained from other studies
considering both normo- and hypertensive obese sub-
jects and the relationship between markers of inflamma-
tion and obesity parameters, especially with newer
indices such as BAI, VAI and WHtR. Therefore we have
formed our conclusions very carefully. Further studies
based on a larger population should be conducted to
evaluate the data from our preliminary research.Conclusions
WHtR is a sensitive index of visceral obesity associated
with chronic inflammation in obese hypertensive sub-
jects. BAI is an obesity index correlated with hsCRP in-
dependently of hypertension and sex. High-sensitivity
CRP is a more sensitive inflammatory marker associated
with obesity indices than IL-6 and TNF-α. It was also
noticed that lipid lowering therapy a significant impact
on obesity-related chronic inflammation. These results
need to be confirmed in larger studies.
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